1. What It Is (Mechanism of Action)

BPC-157 is a 15-amino-acid synthetic sequence derived from a naturally occurring protective peptide isolated from human gastric juice. In preclinical models, it upregulates vascular endothelial growth factor (VEGF), promotes nitric oxide (NO) generation, modulates the FAK-paxillin pathway, and accelerates tendon-to-bone collagen formation.

2. Clinical Indications Under Study

Preclinical investigation of gastric ulceration, inflammatory bowel disease (IBD), tendon, ligament, and muscle transection repair, and ischemic tissue reperfusion.

3. FDA Approval & Regulatory Status

Status:Unapproved for Human Use (FDA 503A Category 2 Safety Risk List)

Unapproved for Human Use (FDA 503A Category 2 Safety Risk List)

4. Human Clinical Evidence Summary

Despite widespread online popularity, BPC-157 lacks completed, peer-reviewed Phase 2 or Phase 3 randomized double-blind human clinical trials validating its efficacy or systemic toxicity profile. Most published literature is restricted to rodent and in vitro models conducted primarily by a single academic group in Zagreb, Croatia.

5. Known Risks, Side Effects & Boxed Warnings

Because BPC-157 strongly stimulates angiogenesis (the growth of new blood vessels via VEGFR2 upregulation), theoretical oncogenic risks exist regarding the proliferation of undetected micro-tumors or neovascularization of malignancies. Long-term systemic toxicity, reproductive safety, and organ clearance rates in humans remain unestablished. Banned in competitive sports by the World Anti-Doping Agency (WADA S0 non-approved substances).

7. Why Gray-Market "Research Chemical" Versions Are Risky

Virtually all BPC-157 sold online is marketed under 'research chemical' disclaimers. Independent lab audits reveal widespread endotoxin contamination, TFA salt residues that cause intense local injection-site irritation, and significant batch-to-batch degradation.
Peptides Agora Intelligence Wire
Weekly Research Brief

Get Breaking BPC-157 Clinical Trial Alerts

Receive verified FDA dockets, Phase 3 readouts, and independent HPLC lab audits directly from our medical journalism desk.

HPLC Purity Audits
Independent lab test readouts & endotoxin assays
FDA PCAC Advisory
503A / 503B compounding votes and legal dockets
Phase 2/3 Readouts
Incretin & repair peptide clinical trial data
Zero vendor sponsorship or commercial advertisingUnsubscribe anytime with one click

8. Questions to Ask a Licensed Clinician

If you are discussing this compound with your doctor or healthcare provider, consider bringing these evidence-based questions:

  • Q1: Why did the FDA Pharmacy Compounding Advisory Committee vote to restrict BPC-157 compounding?
  • Q2: What are the potential angiogenic and oncogenic risks associated with unregulated growth factor peptides?
  • Q3: What evidence-based, FDA-approved alternatives exist for my musculoskeletal injury or gastrointestinal condition?

9. Primary Peer-Reviewed Sources & Citations

  • [1] U.S. FDA Pharmacy Compounding Advisory Committee. Safety Review of BPC-157 (Bulk Drug Substances). 2023 PCAC Briefing Docket. PubMed / Source →
  • [2] World Anti-Doping Agency (WADA). The Prohibited List: Category S0 (Non-approved substances). PubMed / Source →
  • [3] Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des. 2018;24(18):1972-1989. PubMed / Source →